This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Essential cookies enable basic functions and are necessary for the website to function properly.
Statistics cookies collect information anonymously. This information helps us to understand how our visitors use our website.
Marketing cookies are used by third parties or publishers to display personalized advertisements. They do this by tracking visitors across websites.

Press Archive

Category
Year

Joint Venture will enable ITM and Gaotong to jointly expand presence in China and further increase the availability of high-quality medical…

Read more

ITM today announced the establishment of a Chinese subsidiary in Shanghai, that will be part of the ITM Group as a wholly foreign-owned entity (WFOE)…

Read more

Financing led by Petrichor Healthcare Capital Management strengthens company’s global position as a leader in precision oncology and the field of…

Read more

First pivotal study to compare PRRT in patients with Grade 1 and 2 GEP-NETs with approved standard of care

Read more

ITM has signed two strategic agreements with Telix for the global supply of ITM’s highly pure therapeutic radioisotope no-carrier-added Lutetium-177

Read more

ITM will present an e-poster on the COMPETE phase III trial with lead candidate n.c.a. 177Lu-Edotreotide, a Targeted Radionuclide Therapy for GEP-NETs

Read more

GeGant® for the U.S. market will be produced and distributed by ITM’s long-term partner RadioMedix

Read more

The scientific event hosted by ITM saw nuclear medicine and oncology experts discuss “Challenges and Innovative Approaches in the Management of…

Read more

ITM Medical Isotopes GmbH and Isogen signed a formal supply arrangement to provide a reliable supply of Lutetium-177 to the world’s health care system…

Read more

ITM Medical Isotopes GmbH and Isogen signed a formal supply arrangement to provide a reliable supply of Lutetium-177 to the world’s health care system…

Read more

Validation, testing and training will start on a mock-up isotope production system in fall 2020

Read more

ITM’s long-term partner RadioMedix is producing and distributing GeGant® for the U.S. market.

Read more

Future-oriented supply agreements for no-carrier-added Lutetium-177 based Targeted Radionuclide Therapy for prostate cancer patients

Read more

ITM’s subsidiary ITG Isotope Technologies Garching GmbH to be incorporated by name under the ITM family brand

Read more

Future-oriented and long-term alliance with Endocyte for the further expansion of targeted radioligand therapy with no-carrier-added Lutetium-177 for…

Read more

Funds will support ITM’s research and development strategy for cancer treatments

Financing by EU bank is provided under Investment Plan for Europe

Read more

ITM wins German Medical Award in the category “Medical Innovation Product” for outstanding patient benefit and advanced treatment approach with…

Read more

Technology license agreement for the production and distribution of ITM Germanium-68/Gallium-68 Generators and no-carrier-added (n.c.a) Lutetium-177…

Read more

Two partnership agreements signed today will lay the groundwork for a new isotope delivery system at Bruce Power that will help provide lifesaving…

Read more

ITM's subsidiary ITG and Nordic Nanovector have signed long-term global supply agreements for the medical radioisotope n.c.a. 177Lu / EndolucinBeta®

Read more

Förderung des FORActinium-Projekts durch die Bayerische Forschungsstiftung zur Entwicklung eines Herstellungsverfahrens für das in der zielgerichteten…

Read more

Key requirements met to start Ytterbium-176 irradiation at Bruce Power’s facilities for the production of ITM´s no-carrier-added Lutetium-177 for…

Read more

ITM announced today the appointment of Mona M Wahba, MD, MSM to the position of Deputy Chief Medical Officer.

Read more

Conclusion of an exclusive licensing and development agreement for Solucin® Targeted Radionuclide Therapy (TRT) in South Korea.

Read more

ITM announced today the appointment of Michael Lee-Chin to its supervisory board, starting May 23, 2019.

Read more

ITM announced today the lease of a new building in Neufahrn near Munich to increase the production capacity of no-carrier-added (n.c.a.) Lutetium-177…

Read more

ITM and UIH to collaborate in marketing and sales of ITM and UIH imaging and related products to clinical customers in China and worldwide.

Read more

The companies to combine their technologies to develop novel theranostic radiopharmaceuticals.

Merck to supply folate derivatives for the preparation…

Read more

Strategic Partnership supports Commercialization beyond ongoing Phase 3 VISION Trial of 177Lu-PSMA-617

Read more

Bruce Power to secure global supply of no-carrier-added Lutetium-177 through 2064.

ITM to achieve new scalability of n.c.a Lutetium-177…

Read more

Recruitment in the U.S. for the COMPETE trial to begin shortly.

Solucin® studied as a first-line therapy.

Exclusively-produced…

Read more

ITM receives marketing authorization for a ready-to-use radiopharmaceutical in 3 European countries. TOCscan® will be the companion diagnostic in…

Read more

Acknowledgement of ITM’s success in bringing a new promising therapy in Precision Oncology to market and to the patients

Read more

Mit der Unterstützung der Initiative „Diversity als Chance – die Charta der Vielfalt der Unternehmen in Deutschland“ setzt ITM Isotopen Technologien…

Read more

Endocyte, Inc., and ITM Isotopen Technologien München AG (ITM) today announced a supply agreement under which ITM will supply to Endocyte the medical…

Read more

First Patient enrolled in Europe for the clinical study COMPETE at the University Hospital Marburg, Germany.

COMPETE to investigate a broad…

Read more

ITM’s subsidiary ITM Solucin lead 2-day-event focused on study update and efficient trial execution.

Meeting attended by over 60 investigators as…

Read more

With a 174 % growth, ITM Isotopen Technologien München AG is one of the 50 winners of the Deloitte Technology Fast 50 Award 2017

Read more

Clinical development of Targeted Radionuclide Therapies to get major boost Investment will support growth initiatives of the company

Read more